Celltrion’s Rituximab Biosimilar Enjoys A Market Share Of More Than A Third In Europe

 
• By Dean Rudge
  
PumpkinPie
Celltrion's slice of the European rituximab market is around 35% • Source: Shutterstock

More from Biosimilars

More from Products